SCHEMBL14198530

SCHEMBL14198530

CS(=O)(=O)Oc1ccccc1C(=O)Oc1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.70
CYP1A2 P05177 2/20 0.66
CYP2C9 P11712 2/20 0.66
CYP2C19 P33261 1/20 0.66
HSD17B10 Q99714 3/20 0.53
HPGD P15428 2/20 0.53
ALOX15 P16050 1/20 0.53
ALDH1A1 P00352 3/20 0.52
TSHR P16473 1/20 0.52
KMT2A Q03164 1/20 0.52
KDM4E B2RXH2 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
LMNA P02545 3/20 0.49
XBP1 P17861 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
PTGS2 P35354 1/20 0.46
SLC6A3 Q01959 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
TMPRSS15 P98073 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10572563 0.83 MAPT (1.00) MAPTCYP1A2CYP2C9CYP2C19HSD17B10
SCHEMBL648371 0.81 L3MBTL1 (0.69) MAPTHSD17B10ALDH1A1TSHRKMT2A
SCHEMBL2478066 0.81 KDM4E (0.56) MAPTCYP1A2CYP2C9CYP2C19HSD17B10
SCHEMBL2149614 0.80 MAPT (0.71) MAPTCYP1A2CYP2C9CYP2C19HSD17B10
SCHEMBL28485370 0.79 MAPT (0.59) MAPTCYP1A2CYP2C9CYP2C19HSD17B10
Phenylaspirinate SCHEMBL29389369 0.78 HSD17B10 (0.75) MAPTCYP1A2CYP2C9CYP2C19HSD17B10
Phenylaspirinate SCHEMBL25954 0.78 HSD17B10 (0.75) MAPTCYP1A2CYP2C9CYP2C19HSD17B10
SCHEMBL4731724 0.78 LMNA (0.51) MAPTCYP1A2CYP2C9CYP2C19HSD17B10
SCHEMBL5710896 0.78 HSD17B10 (0.64) MAPTCYP1A2CYP2C9CYP2C19HSD17B10
SCHEMBL1282647 0.78 HSD17B10 (0.64) MAPTCYP1A2CYP2C9CYP2C19HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080081914-A1 PROCESS FOR THE PREPARATION OF BENZO [D] ISOXAZOL-3-YL-METHANESULFONIC ACID AND THE INTERMEDIATES THEREOF DIPHARMA S.P.A. (IT) 2008-04-03 US disclosed
US-7291742-B2 Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof DIPHARMA S.P.A. (IT) 2007-11-06 US disclosed
US-7291742-B2 Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof DIPHARMA S.P.A. (IT) 2007-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081914-A1 PROCESS FOR THE PREPARATION OF BENZO [D] ISOXAZOL-3-YL-METHANESULFONIC ACID AND THE INTERMEDIATES THEREOF GABRD, GABRA5, GABRA6 MAPT 2095/4885CYP1A2 83/4885CYP2C9 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.